Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.
Kari Hacker, MD, PhD
Advertisement
Articles by Kari Hacker, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5